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Background: Laparoscopic liver resections for malignancy are increasing worldwide, and yet data from
North America are lacking. We aimed to assess the long-term outcomes of patients undergoing laparoscopic liver resection and open liver resection as a treatment for hepatocellular carcinoma.
Methods: Patients undergoing liver resection for hepatocellular carcinoma between January 2008 and
December 2019 were retrospectively studied. A propensity score matching was performed using patient demographics, laboratory parameters, etiology of liver disease, liver function, and tumor characteristics. Primary
outcomes included overall survival and cumulative incidence of recurrence. Kaplan-Meier and competing risk
cumulative incidence were used for survival analyses. Multivariable Cox regression and Fine-Gray proportional
hazard regression were performed to determine hazard for death and recurrence, respectively.
Results: Three hundred and ninety-one patients were identiﬁed (laparoscopic liver resection: 110; open
liver resection: 281). After propensity score matching, 149 patients remained (laparoscopic liver resection: 57; open liver resection: 92). There were no signiﬁcant differences between groups with regard to
extent of hepatectomy performed and tumor characteristics. The laparoscopic liver resection group
experienced a lower proportion of Clavien-Dindo grade III complications (14% vs 29%; P ¼ .01). In the
matched cohort, the 1-, 3-, and 5-year overall survival rate in the laparoscopic liver resection versus open
liver resection group was 90.9%, 79.3%, 70.5% vs 91.3%, 88.5%, 83.1% (P ¼ .26), and the cumulative incidence of recurrence 31.1%, 59.7%, 62.9% vs 18.9%, 40.6%, 49.2% (P ¼ .06), respectively.
Conclusion: This study represents the largest single institutional study from North America comparing
long-term oncologic outcomes of laparoscopic liver resection and open liver resection as a treatment for
primary hepatocellular carcinoma. The combination of reduced short-term complications and equivalent
long-term oncologic outcomes favor the laparoscopic approach when feasible.
© 2021 Elsevier Inc. All rights reserved.
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Introduction

Patient selection and surgical technique

Hepatocellular carcinoma (HCC) represents the fourth leading
cause of cancer-related death in the world, and its incidence continues to increase in the United States.1,2 In the 5% to 10% of patients
with a single lesion HCC and well-compensated liver disease, liver
resection remains the treatment of choice according to European
and American guidelines.3,4 The use of laparoscopic surgery for
liver resections (LLR) in HCC has increased worldwide and represents an attractive alternative to conventional open liver surgery
(OLR) because it has potential to mitigate perioperative risks and
accelerate postoperative functional recovery.5e7
Although high-quality randomized trials comparing LLR and
OLR for various stages of HCC are lacking, previous retrospective
reports have demonstrated favorable short-term outcomes with
the laparoscopic approach.5,8e12 As a result of its relatively recent
adoption for HCC resection, lack of long-term clinical follow-up
after LLR has limited conclusions of early studies. Additionally,
many prior reports included a lower number of major laparoscopic
hepatectomies, which may have conferred a potentially unfair
oncological advantage to laparoscopic resection. Furthermore, as
the majority of series are from Europe and Asia, differences in the
patient populations make generalizability challenging.13e15 Lastly,
due to inherent selection bias with retrospective study design,
rigorous risk adjustments between groups is imperative, but has
been inconsistent and shallow.
Given increased interest in expanding LLR for HCC, we aimed
to evaluate the long-term outcomes of patients undergoing
laparoscopic versus open resection as a treatment for HCC. We
sought to address the aforementioned limitations of prior reports
through study of patients from a high-volume North American
center and by performing a granular propensity score matched
analysis.

In general, all patients with HCC are presented in a multidisciplinary meeting. After the decision is made to proceed with liver
resection, the feasibility of a laparoscopic approach is evaluated. As
a rule of thumb, patients who are not considered for laparoscopic
resection include patients where vascular reconstructions or an
ex vivo procedure is anticipated. Additionally, patients with
advanced cirrhosis with portal hypertension that are surgical candidates are typically deferred to a laparoscopic approach. Patients
requiring a minor hepatectomy, even in the presence of mild portal
hypertension, are considered for resection if the approach is LLR. In
some instances, HVPG will be measured, and in those with a
gradient <15 mm Hg we will consider proceeding with resection. In
considering and performing LLR in such patients, factors that are
taken into account include trocar placements (eg, avoiding the
midline), the extent of the surgery (major hepatectomy versus
minor), and the medical risk and severity of the portal hypertension. Furthermore, in some patients, we will proceed with a laparoscopic approach with a low threshold for conversion. These may
include patients with certain medical comorbidities such as heart
disease, which is challenging to manage given the required low
central venous pressure. In addition, a patient with an extensive
upper abdominal surgical history may still be considered for a
laparoscopic approach with a low threshold of conversion if timely
intraoperative progression cannot be achieved. Overall, the institution has evolved to pursue a minimally invasive surgical
approach as often as possible in patients with HCC. Anatomic
resection was the preferred surgical technique. However, a nonanatomical or segmental approach was employed if an adequate
margin could be obtained and allowed for parenchymal sparing in
patients with cirrhosis. A standard technique for LLR has been
previously described.17 Venous and portobiliary pedicles were
ligated with vascular stapling devices when necessary. Parenchymal transection was performed with electrocautery in combination with water-jet dissection (Helix Hydrojet, ERBE and AMT
Electrosurgery) in OLR. For LLR, the Cavitron ultrasonic surgical
aspirator (CUSA: Integra LifeSciences Corporation, NJ), water-jet,
and ultrasonic shears were used for ﬁne parenchymal dissection.

Methods
This study was approved by our institutional REB (REB
#16e5626), and a waiver of informed consent was obtained.
Study population

Covariates

We retrospectively studied consecutive adults (18 years)
who underwent LR for HCC between January 2008 and December
2019 at a single academic institution. Patients with LR before
2008 were excluded because the laparoscopic approach was not
used at the institution before that time. Patients resected after
2019 were excluded to allow for enough follow-up time to
evaluate tumor recurrence after LR. At the time of analysis, patient data were up to date as of March 13, 2021. The diagnosis of
HCC was established according to the American Association for
the Study of Liver Diseases guidelines.3 To perform a sensitivity
analysis for the assessment of outcomes over time, the study
period was further categorized into an early era (2008e2013) and
a late era (2014e2019) to allow an equal number of years in both
groups. Patients with mixed hepatocellular carcinomacholangiocarcinoma and those with ﬁbrolamellar subtype on
pathology were excluded. Moreover, patients were excluded if
they had a previous liver transplant, locoregional treatment
(including, but not limited to, radiofrequency ablation, transarterial chemoembolization, and microwave ablation), tumor
rupture, prior liver resection, or missing pathology reports
(Figure 1). This study complies with the STROBE statement for
observational studies.16

We recorded patient age, sex, body mass index, etiology of liver
disease, previous non-liver upper abdominal surgery, preoperative
portal vein embolization, Barcelona Clinic Liver Cancer stage, degree of liver dysfunction (model for end-stage liver disease and
Child-Pugh score), laboratory variables (albumin, total bilirubin,
international normalized ratio, albumin-bilirubin grade, and
platelet count), American Society of Anesthesiologists score, preoperative tumor characteristic (including size, number, and satellite
lesions), pathology ﬁndings, and postoperative outcomes including
length of stay. Major hepatectomy was deﬁned as complete resection of 3 or more liver segments according to the Brisbane 2000
terminology.18 The difﬁculty of hepatectomy was dichotomized
according to whether a full anatomic segmentectomy was performed of segment 1, 4A, 7, and/or 8.19,20 AFP was categorized to
reﬂect clinically relevant categories (ng/mL, <20, 20e99, 100e999,
and >1000).21 Pathology characteristics included the size of the
largest tumor, tumor number, presence of satellite lesions, tumor
differentiation, microvascular invasion, macrovascular invasion,
surgical margin positivity, surgical margin distance, and Laennec
stage of adjacent liver ﬁbrosis. Tumor differentiation was deﬁned
according to the modiﬁed Edmondson criteria.22 Postoperative
complications occurring within 90 days of the resection were
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Figure 1. Flow chart of selection criteria.

graded using the Clavien-Dindo classiﬁcation system.23 Liver failure
and grade of liver failure according to grade A, B, and C was
recorded for the ﬁrst 30 days after resection according to the International Study Group of Liver Surgery deﬁnition.24 Intraoperative variables included operative time (in minutes), packed
red blood cell transfusion (in mL), fresh frozen plasma transfusion
(in mL), platelet transfusion (in mL), estimated blood loss (in mL),
and Pringle maneuver used (binary).

contrast-enhanced computed tomography, contrast-enhanced ultrasound, or magnetic resonance imaging.3 Overall survival was
calculated from the day of resection to the day of death or last
known contact. The time to recurrence was calculated from the day
of resection to the ﬁrst imaging study that conﬁrmed tumor
recurrence.

Outcome measures

Descriptive data were expressed as medians and interquartile
ranges (IQR). These were compared using the Mann-Whitney U
tests. Categorical variables were expressed using numbers and
percentages (%). These were compared using c2 and Fisher exact
tests. Overall survival was estimated using the Kaplan-Meier
method, and groups were compared with log-rank tests. A univariable Cox proportional hazard regression model was constructed
after matching to assess the association between the exposure of
interest (LLR versus OLR) and mortality. The proportional hazard
assumption was assessed using Schoenfeld residuals against the
transformed time. Instead of the Kaplan-Meier method, which
censors for the competing event of death, a cumulative incidence
approach was used to account for the presence of a competing risk
of death with recurrence.26 The cumulative incidence was estimated using subdistribution estimates for each cause. A Gray’s
modiﬁed log-rank test was used to compare subdistribution estimates for each cause and to evaluate the quality of the cumulative
incidence curve. To assess for the relative change in the hazard of
recurrence, a Cox proportional hazard model using Fine-Gray
competing risk was used to account for death as a competing
event.27 All 2-sided P values less than 0.05 were considered statistically signiﬁcant. Statistical analyses were performed using R
(version 4.0.3 2020, R Foundation for Statistical Computing, Vienna,
Austria). Matching was performed using the package MatchIt.

The study’s primary endpoints were post-LR survival and HCC
tumor recurrence. In this study, the primary exposure, intended
surgical approach (LLR versus OLR), was not a time-varying
covariate.
Propensity score matching
A propensity score was constructed based on the predicted
probability of receiving laparoscopic surgery using logistic/probit
regression (intention to treat). This was performed to control for
the effect of confounding and the method chosen to address selection bias. Covariates selected included the following: age; sex;
body mass index; extent of resection (major hepatectomy); unfavorable tumor segment; largest preoperative tumor size and
number; preoperative satellite lesion; Child-Pugh score; platelet
count; albumin-bilirubin grade; etiology of liver disease; year of
resection; and preoperative AFP. A sensitivity analysis was performed using only nonconversion cases. Matching was performed
for the dependent variable of exposure (LLR versus OLR) using
these covariates. The matching method used was a nearest
neighbor matching method without replacement with a caliper of
0.1. Matching quality was evaluated with standardized mean differences between the treated and control groups. A difference of
<0.2 standardized mean difference between covariates included in
the match was used as the threshold of a negligible imbalance
between groups.25
Follow-up, survival, and recurrence
Postoperatively, patients were followed with AFP and contrastenhanced computed tomography of the chest and abdomen or ultrasound in 3-month intervals for the ﬁrst 2 years, then every 6
months for 2 years, and yearly thereafter. In the case of a suspected
recurrence, additional imaging studies were obtained, including

Statistical analysis

Results
Study population and pathology
Three hundred and ninety-one patients underwent liver resection for HCC over the study period with the number of LLRs performed having increased over time (Supplementary Figure S1). One
hundred and ten patients were intended for a laparoscopic
approach, and 14 required conversion to open. The reasons for
conversion were hemorrhage (n ¼ 4), poor visualization (n ¼ 3),
anatomic issues (n ¼ 3), inability to progress (n ¼ 2), technical
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problems with a device (n ¼ 1), and other (n ¼ 1). In total, 96 (25%)
resections were completed laparoscopically and 295 (75%) open.
There was a higher proportion of major hepatectomies in the OLR
group (28% vs 57%; P < .001). The baseline characteristics of patients in the LLR and OLR groups are summarized in Table I and
Supplementary Table S1. Most preresection patient characteristics
were similar between groups. Patients in the LLR group had smaller
tumors preoperatively (cm [IQR], 4.20 [3.30e5.90] vs 5.10
[3.60e8.70]; P < .001) and on pathology (cm [IQR], 4.50 [3.30e6.07]
vs 5.50 [3.80e8.50]; P < .001). The LLR group also had more solitary
tumors (92% vs 80%; P ¼ .01) and lower rates of microvascular invasion (45% vs 60%; P ¼ .02). The median length of follow-up was
2.84 years (IQR 1.39e5.41). The use of the Pringle maneuver
increased over the study period, with a proportionally higher increase in the LLR group over time (Supplementary Figure S2).
Length of stay was shorter in the LLR group (median [IQR] 5 [3e6]
vs 7 [5e10]; P < .001). The LLR group experienced a lower proportion of Clavien-Dindo grade III or greater complications (15% vs
26%; P < .001) (Table II).
Survival analysis in the unmatched cohort
The OS was similar between the LLR and OLR groups (Figure 2).
Short-term survival was equivalent between the groups (30 days

LLR 96.3% [95% CI 92.9e99.9] versus OLR 96.8% [95% CI 94.7e98.9];
P ¼ .82; 90 days LLR 96.3% [95% CI 92.9e99.9] versus OLR 93.6%
[95% CI 90.7e96.5]; P ¼ .31). The 1-, 3-, and 5-year survival rates
were: LLR 90.9% (95% CI 83.6e98.8), 73.9% (95% CI 68.5e91.9), 70.5%
(95% CI 56.6e87.8) versus OLR 91.3% (95% CI 85.7e97.2), 88.5% (95%
CI 82.0e95.5), 83.1% (95% CI 74.8e92.3) (P ¼ .26). Similarly, there
was no statistically signiﬁcant difference in the 1-, 3-, and 5-year
cumulative incidence of HCC recurrence: LLR 31.1% (95% CI
19.3e43.6), 59.7% (95% CI 43.7e72.5), and 62.9% (95% CI 46.3e75.6)
versus OLR 18.9% (95% CI 11.5e27.6), 40.6% (95% CI 30.0e50.9), and
49.2% (95% CI 37.3e60.1) (P ¼ .06) (Figure 3).
Survival analysis in the unmatched cohort stratiﬁed by eras
Short-term survival in the early were equivalent (30 days LLR
94.9% [95% CI 88.2e100] versus OLR 97.7% [95% CI 95.2e100]; P ¼
.35; 90 days LLR 94.9% [95% CI 88.2e100] versus OLR 94.7% [95% CI
91.0e98.6]; P ¼ 1.00). The OS in the early era (2008e2013) was
better in the OLR (P ¼ .04) (Supplementary Figure S3, A). The 1-, 3-,
and 5-year survival rates were 89.4% (95% CI 80.0e99.8), 72.1% (95%
CI 58.8e88.5), and 61.6% (95% CI 46.9e80.8) for LLR and 93.9% (95% CI
90.0e98.1), 86.1% (95% CI 80.2e92.5), and 85.2% (95% CI 79.1e91.8)
for OLR (P ¼ .04). Short-term survival in the late era was equivalent
between the groups (30 days LLR 97.2% [95% CI 93.4e100] versus OLR

Table I
Demographics and clinicopathological characteristics
Total n ¼ 391

Before matching

After matching

Lap n ¼ 110 (22%) Open n ¼ 281 (78%) P
Major hepatectomy, 3 segments, number (%) 191 (49)
Unfavorable segments,* number (%)
256 (66)
Sex, male, number (%)
315 (81)
Age, year median (IQR)
64 (56e71)
BMI, median (IQR)
25.1 (22.3e28.4)
Missing
32
Etiology, number (%)
HBV
181 (46)
HCV
86 (22)
ETOH
23 (6)
NASH
20 (5)
HBVþHCV coinfection
2 (1)
Other
32 (8)
No underlying liver disease
47 (12)
Missing
0
Albumin, median (IQR)
42 (39e44)
Missing
33
Total bilirubin, mmol/L, median (IQR)
10 (8e14)
Missing
17
INR, median (IQR)
1.01 (0.97e1.06)
Missing
6
Platelet, median (IQR)
193 (154e245)
Missing
5
ALBI grade, number (%)
1
274 (77)
2
82 (23)
Missing
35
Child Pugh score, number (%)
A5
329 (92)
A6
23 (6)
B7
5 (1)
Missing
34
Preoperative AFP, number (%)
<20
185 (53)
20-99
55 (16)
100e999
54 (16)
>1000
53 (15)
Missing
44

31 (28)
42 (38)
86 (78)
65 (58e72)
26.2 (22.9e29.9)
10

160 (57)
214 (76)
229 (82)
63 (56e71)
24.4 (22.0e27.8)
22

47 (43)
27 (25)
8 (7)
7 (6)
1 (1)
8 (7)
12 (11)
0
41 (39e44)
9
9 (7e12)
7
1.1 (0.96e1.08)
3
186 (148e226)
2

134 (48)
59 (21)
15 (5)
13 (5)
1 (0)
24 (9)
35 (13)
0
42 (39e43)
24
11 (8e15)
10
1.1 (0.97e1.06)
3
194 (155e255)
3

79 (80)
20 (20)
11

195 (76)
62 (24)
24

93 (95)
4 (4)
1 (1)
12

236 (91)
19 (7)
4 (2)
22

65 (63)
17 (16)
15 (14)
7 (7)
6

120 (49)
38 (16)
39 (16)
46 (19)
38

SMD Lap n ¼ 57 (38%) Open n ¼ 92 (62%) P

SMD

<.001
<.001
.55
.20
.01

0.61
0.83
0.08
0.18
0.31

.71
.14
1.00
.61
.21

0.09
0.05
0.02
0.03
0.20

.85

0.18

-

0.04

.95

0.006

.16

0.29

.69

0.07

.54

0.05

.79

0.08

-

0.04

.82

0.16

.89

0.08

.004

0.37

.93

0.08

.07

0.28

.52

0.10

.49

.02

21 (37)
28 (49)
48 (84)
64 (56e72))
26.0 (23.5e28.2)
0

38 (41)
51 (55)
78 (85)
66 (58e73)
25.1 (22.0e28.0)
0

30 (53)
11 (19)
2 (4)
3 (5)
0 (0)
4 (7)
7 (12)
0
42 (39e44)
0
9 (8e13)
0
1.02 (0.95e1.08)
0
191 (145e226)
0

59 (56)
23 (22)
5 (5)
5 (5)
0 (0)
5 (5)
9 (9)
0
42 (40e44)
0
11 (8e13)
0
1.1 (0.98e1.05)
0
172 (148e216)
0

52 (79)
14 (21)
0

83 (78)
23 (22)
0

54 (95)
3 (5)
0 (0)
0

88 (96)
4 (4)
0 (0)
0

36 (63)
8 (14)
8 (14)
5 (9)
0

51
15
15
11
0

0.15

0.39
(55)
(16)
(16)
(12)

AFP, alfa fetoprotein; ALBI, albumin-bilirubin; BMI, body mass index; ETOH, alcoholic liver disease; HBV, hepatitis B virus; HCV, hepatitis C virus; INR, international normalized
ratio; IQR, interquartile range; NASH, nonalcoholic steatohepatitis; SMD, standardized mean difference.
*
Segment 1, 4A, 7, and/or 8.
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Table II
Pathology and postoperative variables
Total n ¼ 391

Tumor size at pathology,
cm, median (IQR)
Satellite lesion/s path,
number (%)
Tumour solitary at path,
number (%)
Tumor differentiation,
number (%)
Well diff.
Mod diff
Poor
Missing
Severe ﬁbrosis or cirrhosis,
number (%)
Missing
Microvascular invasion,
number (%)
Missing
Macrovascular invasion,
number (%)
Missing
Positive margins,
number (%)
Missing
Margin distance, cm
median (IQR)
Missing
Follow-up, years, median
(IQR)
Era of resection, number (%)
2008e2013
2014e2019
LOS days, median (IQR)
Missing
Complications within 90
days, number (%)
No
Clavien-Dindo 1e2
Clavien-Dindo 3
Liver failure within 30 days,
number (%)
Grade of liver failure,
number (%)
Grade A
Grade B
Grade C
OR time, minutes, median
(IQR)
pRBC transfusion (mL),
median (IQR)
FFP transfusion (mL),
median (IQR)
Platelet transfusion (mL),
median (IQR)
Estimated blood loss (mL),
median (IQR)
Pringle, number (%)

Before matching

After matching

Lap n ¼ 110
(22%)

Open n ¼ 281
(78%)

P

SMD

Lap n ¼ 57 (38%)

Open n ¼ 92
(62%)

P

SMD

5.20
(3.50e8.00)
45 (12)

4.50
(3.30e6.07)
6 (6)

5.50
(3.80e8.50)
39 (14)

<.001

0.56

5.00 (3.60e6.50)

.64

0.04

.03

0.29

4 (7)

4.85
(3.50e6.39)
8 (9)

.96

0.06

327 (84)

101 (92)

226 (80)

.01

0.33

54 (95)

83 (90)

.50

0.17

.03

0.27

.26

0.27

18 (5)
302 (78)
69 (18)
2
260 (67)

10
83
17
0
81

(74)

8 (3)
219 (79)
52 (19)
2
165 (64)

0.22

4 (7)
44 (77)
9 (16)
0
41 (72)

2 (2)
78 (86)
11 (12)
1
59 (64)

.08

.42

0.17

0
214 (56)

0
49 (45)

0
165 (60)

.02

0.29

0
25 (45)

0
43 (47)

.56

0.09

7
44 (11)

2
6 (6)

5
38 (14)

.03

0.28

1
5 (9)

1
7 (8)

.71

0.04

3
13 (3)

0
1 (1)

3
12 (4)

.17

0.21

0
1 (2)

1
6 (7)

.50

0.14

2
0.80
(0.30e1.50)
4
2.84
(1.39e5.41)

0
1.10
(0.52e1.98)
0
2.28
(1.24e4.04)

2
0.70
(0.20e1.50)
4
3.240
(1.45e5.89)

<.001

0.40

0
1.00 (0.50e1.90)

.01

0.49

.008

0.32

0
2.77 (1.53e4.15)

1
0.60
(0.20e1.40)
2
4.18
(2.07e6.04)

.02

0.37

.04

0.24

.37

0.003

172 (44)
219 (56)
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<.001
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diff, differentiation; FFP, fresh frozen plasma; IQR, interquartile range; LOS, length of stay; LR, liver resection; OR, operating room; path, pathology; pRBC, packed red blood cells;
SMD, standardized mean difference.

95.9% [95% CI 92.8e99.2]; P ¼ .66; 90 days LLR 97.2% [95% CI
93.4e100] versus OLR 92.5% [95% CI 88.4e96.9]; P ¼ .19). In contrast,
the OS was similar between LLR and OLR in the late era (2014e2019)
(P ¼ .65) (Supplementary Figure S3, B). The 1-, 3-, and 5-year survival
rates were 94.1% (95% CI 88.6e99.9), 78.3% (95% CI 66.6e92.1), and
73.7% (95% CI 60.3e90.1) for LLR and 87.4% (95% CI 82.1e93.0), 80.6%
(95% CI 73.3e88.7), and 65.0% (95% CI 53.8e78.6) for OLR. The
cumulative incidence of recurrence was similar in the early and late

eras (P ¼ .37 and P ¼ .61, respectively) (Supplementary Figure S4,
AeB, respectively)
Causes of death
In the LLR group, the most common cause of death was progressive HCC (n ¼ 11 [46%]) followed by cardiorespiratory failure
(n ¼ 3 [13%]). In the OLR group, progressive HCC represented the
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Figure 2. Overall survival after liver resection (overall cohort).

main cause of death (n ¼ 23 [40%]), followed by postoperative
complications (n ¼ 7 [12%]) and liver failure (n ¼ 6 [10%]).
Matched cohort
After PSM, 57 patients in the LLR group were matched with 92
patients in the OLR group. There were no signiﬁcant differences
between the groups with regard to the extent of hepatectomy
performed and tumor characteristics. The LLR group had shorter
LOS (5 [3e6] vs 6 [5e10]; P < .001) and lower estimated blood loss
(median [IQR] 400 [200e800] vs 700 [400e1300]; P ¼ .001). The
groups were similar in intraoperative transfusion requirements.
The LLR group had a similar rate of margin positivity but a larger
margin distance compared with the OLR group (cm median [IQR]
1.00 [0.50e1.90] vs 0.60 [0.20e1.40]; P ¼ .01). There was no statistically signiﬁcant difference between posthepatectomy liver
failure or grade of liver failure between the groups. The proportion
of Clavien-Dindo grade III or greater complications were lower in
the LLR group (14% vs 29%; P ¼ .01) (Table II).
Matched survival analysis
Short-term survival was similar between the groups (30 days
LLR 96.5% [95% CI 91.8e100] versus OLR 96.7% [95% CI 93.2e100];
P ¼ .94; 90 days LLR 96.5% [95% CI 91.8e100] versus OLR 92.4% [95%
CI 87.1e98.0]; P ¼ .33). There were no statistically signiﬁcant

differences in OS (1-, 3-, and 5-year LLR 90.9% [95% CI 83.6e98.8],
79.3% [95% CI 68.5e91.9], 70.5% [95% CI 56.6e87.8] versus OLR
91.3% [95% CI 85.7e97.2], 88.5% [95% CI 82.0e95.5], 83.1% [95% CI
74.8e92.3]; P ¼ .26) (Figure 4) and risk of HCC recurrence (1-, 3-,
and 5-year LLR 31.1% [95% CI 19.3e43.6], 59.7% [95% CI 43.7e72.5],
62.9% [95% CI 46.3e75.6] versus OLR 18.9% [95% CI 11.5e27.6], 40.6%
[95% CI 30.0e50.9], 49.2% [95% CI 37.3e60.1]; P ¼ .06) (Figure 5).
The hazard of death (LLR HR 1.55, 95% CI 0.65e3.30; P ¼ .26) and
recurrence (LLR subdistribution HR 1.39, 95% CI 0.88e2.21; P ¼ .16)
was equivalent between the groups. For patients who recurred, the
pattern of recurrence did not differ between the groups (margin
recurrence LLR n ¼ 8 [25%] versus OLR 8 [19%]; P ¼ .50). Patients
requiring conversion from LLR to OLR had a similar survival as those
who were completed laparoscopically (P ¼ .20).
Discussion
As the prevalence of HCC continues to increase, along with the
adoption of laparoscopic liver surgery as a modality for its treatment, it remains paramount to conduct contemporary analyses of
this approach on outcomes. The current study represents the
largest single institutional study from North America, evaluating
short- and long-term outcomes of LLR and OLR for the treatment of
HCC. After granular propensity score matching was performed using patient demographics, tumor characteristics, and extent of
resection, there was a signiﬁcantly shorter operative time, shorter
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Figure 3. Cumulative incidence of recurrence after liver resection (overall cohort).

LOS, lower estimated blood loss, and larger margin distance for
patients undergoing LLR. The major complication rate was lower in
the LLR group. Long-term outcomes including OS and HCC recurrence were equivalent.
There has been a considerable increase in the use of LLR over the
last 2 decades.8 Increasing experience has enabled expansion of the
LLR technique to safely include major hepatectomies and resection
of HCC located in unfavorable locations.28e30 Prior reports have
assessed short-term outcomes of LLR and demonstrated less perioperative blood loss and transfusion requirement, shorter length of
stay, and lower morbidity and mortality.28,31 We similarly found
that LLR resulted in a shorter LOS, lower blood loss, and a lower
postoperative complication rate. There were no differences between groups in terms of short-term mortality (30- and 90-day).
The LLR group had a larger surgical margin distance, which may
possibly provide bias toward a more liberal resection margin with
the new technique. Nonetheless, it remains unclear what, if any,
this small difference between the groups may have where the
pattern of recurrence (margin and non-margin) was not statistically signiﬁcantly different between the groups. With regard to
long-term oncologic outcomes, several studies, primarily from Asia,
have demonstrated equivalent overall and disease-free survival,
which has been corroborated by meta-analyses.6,9,11e15,31e33 As the
etiology of HCC in East Asia is predominantly related to hepatitis B,
this differs substantially from patients in North America who tend
to have a higher proportion of hepatitis C virus-related HCC and
makes these reports difﬁcult to generalize.34 Speciﬁcally, hepatitis
C virus-related HCC has been associated with a shorter disease-free
survival than hepatitis Berelated HCC.34 Despite this, however, we
similarly noted equivalent oncologic outcomes of the LLR group,
suggesting that surgical approach does not impact outcomes even
when disease etiology is accounted for.

Accounting for potential confounders is imperative to most
appropriately assess the impact of technique on outcome.
Recently, Ruzzenente et al evaluated a sizeable multi-institutional
cohort of HCC patients with portal hypertension using PSM.35 A
total of 1,974 patients were included, with a subsequent 1:1
match of 407 LLR and OLR patients. Although the patient population was different, their study demonstrated similar ﬁndings to
our report with short-term results favoring the LLR approach and
long-term outcomes being equivalent. Another study used the
United States National Cancer Database and compared survival
outcomes for 190 matched LLR and OLR patients and found
equivalent overall survival.36 Nonetheless, recurrence was unavailable in the data set and was therefore not examined.36
Indeed, these multi-institutional cohorts and registry studies
can amass a large heterogeneous group of patients, with high
statistical power. Nonetheless, it is remains difﬁcult to elucidate
the exact contribution of individual institutions, which likely
differ in their experience level and thus challenge the interpretation of results. Additionally, in pooling the data together,
favorable outcomes of larger institutional experiences can mask
the outcomes of smaller ones. In the current report, we performed adjustments using a granular PSM on variables most likely
to impact long-term outcomes, such as degree of liver disease,
preoperative biomarker (AFP) level, and tumor variables. Moreover, as prior studies inconsistently accounted for varying oncologic outcomes over time as institutional/provider experience
with LLR increased, we also matched based on the year of
resection. Within this context, we observed decreased long-term
survival in patients undergoing LLR in the early era compared
with OLR. In contrast, in the later era survival was equivalent
between the 2 approaches. The reason for decreased survival in
the early era is unclear but may be a result of sample size bias.
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Figure 4. Overall survival after liver resection in the matched cohort univariable Cox proportional hazard Lap (ref: open) HR 1.55, 95% CI 0.65e3.30; P ¼ .26.

The learning curve to achieve proﬁciency with LLR remains to be
fully elucidated. Indeed, the number of cases required to achieve
procedural proﬁciency depends on the extent of hepatectomy, with
fewer required for less extensive approaches.37 Previous studies
have reported the requirement to be 45 to 75 cases for major
hepatectomies, with study endpoints including improvements in
conversion rates, operative time, blood loss, and morbidity.38e41
Although these studies have not speciﬁcally evaluated outcomes
of HCC patients, these abovementioned numbers represent a
valuable benchmark in implementing LLR from a programmatic
standpoint. Our study was not designed to directly evaluate the
learning curve of LLR. It does, however, highlight that an appropriate resection margin can be achieved using this technique,
resulting in equivalent oncologic outcomes to the OLR approach.
As randomized controlled trials between LLR and OLR are
desperately needed, they are contingent on the surgical performance of a new technique, which in turn depends on provider and
institutional learning curves. Until such high-quality data are
available, iterative appraisal of retrospective outcomes is critical,
given the rapid adoption of this approach. To this end, our group
reported our early institutional experience with the laparoscopic
approach.42 This current study was performed to address the limitations of the prior work, including sample size, a relatively short
follow-up, and ability to perform granular matching on a number of
important clinicopathologic variables. In the previous report, there
was a nonstatistical trend toward a worse DFS in LLR.42 In addition
to the Kaplan-Meier based method for DFS analysis, which censors
for the competing event of death, we used a cumulative incidence
approach to account for this competing risk in the evaluation of

recurrence. In this updated analysis with a longer follow-up and
larger sample size, both DFS and cumulative incidence of recurrence were equivalent between LLR and OLR.
This study is limited by its single-center retrospective nonrandomized study design, with the potential for misclassiﬁcation
and selection bias. Though the sample size of the laparoscopic
cohort is relatively small, it does represent the largest, single-center
experience from North America. The homogeneity afforded by the
single institution center design offers an opportunity to evaluate
temporal trends in outcomes that may be masked by larger heterogeneous multi-center studies, where the experience of some
centers may outweigh those of lower volume institutions and the
granularity of available data is lacking. Though granular PSM was
performed in an attempt to control for the effect of confounding
and address selection bias, there is always the potential for residual
confounding.
In conclusion, the combination of reduced short-term complications and LOS and equivalent long-term oncologic outcomes
favor the laparoscopic approach for resectable patients with HCC
and should be the surgical technique of choice when feasible.
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Figure 5. Cumulative incidence of recurrence after liver resection in the matched cohort (univariable Fine-Gray proportional hazard regression for competing event of recurrence
subdistribution HR 1.39, 95% CI 0.88e2.21; P ¼ .16).

Supplementary materials
Supplementary material associated with this article can be
found, in the online version, at [https://doi.org/10.1016/j.surg.2021.
10.017].
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